The Portfolio returned 0.87% in Q4 2025, trailing its benchmark as sector performance and AI volatility impacted results. Read the full analysis for more details.
Hims & Hers Health, Inc., faces GLP-1 headwinds, volatility, and regulatory risk but has strong revenue growth and global ...
Life science incubator part of UC Berkeley's wider ecosystem, which has consistently ranked the number one university ...
Novo Nordisk will set a $675/month US list price (effective January 1, 2027) for Wegovy, Ozempic, and Rybelsus, targeting affordability for high-deductible and coinsurance designs. Impacted doses ...
The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results